

Supplementary Materials

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer

Susan Dent, Dean Fergusson, Olexiy Aseyev, Carol Stober, Gregory Pond, Arif A. Awan, Sharon F. McGee, Terry L. Ng, Demetrios Simos, Lisa Vandermeer, Deanna Saunders, John F. Hilton, Brian Hutton, and Mark Clemons, on behalf of the REaCT Investigators

Table S1. Baseline Characteristics (Intention to treat population).

| N | | Q3-Monthly 100 | Q4-Monthly 100 |
|---|---------------------------|------------------------|------------------------|
| Patient Characteristics | | | |
| Age | Median (IQR) range | 55.8 (47.1-61.9) 32-83 | 56.1 (47.3-63.1) 28-77 |
| | Mean (sd) | 55.4 (11.3) | 55.0 (11.3) |
| Baseline LVEF | Median (IQR) range | 65 (60-68) 54-82 | 64 (61-67) 54-76 |
| | Mean (sd) | 64.4 (5.4) | 63.9 (4.9) |
| Baseline Modality | N (%) ECHO | 72 (72.0) | 71 (71.0) |
| CV Risk Factors | N (%) Yes | 51 (51.0) | 53 (53.0) |
| CAD Stroke PVD | N (%) Yes | 1 (1.0) | 0 (0.0) |
| Atrial Fibrillation | N (%) Yes | 1 (1.0) | 2 (2.0) |
| Obesity | N (%) Yes | 11 (11.0) | 15 (15.0) |
| Smoking Status | N (%) Non-Smoker | 82 (82.0) | 80 (80.0) |
| | Current Smoker | 5 (5.0) | 7 (7.0) |
| | Past Smoker | 13 (13.0) | 13 (13.0) |
| Hypertension | N (%) Yes | 22 (22.0) | 20 (20.0) |
| Diabetes | N (%) Yes | 9 (9.0) | 3 (3.0) |
| Angina | N (%) Yes | 1 (1.0) | 0 (0.0) |
| Dyslipidemia | N (%) Yes | 12 (12.0) | 7 (7.0) |
| Other Risk Factors* | N (%) Yes | 5 (5.0) | 6 (6.0) |
| Treatments | | | |
| Chemotherapy Type | N (%) Anthracycline Based | 55 (55.0) | 51 (51.0) |
| | N (%) Yes | 79 (79.0) | 69 (69.0) |
| Radiation On-Study | Median (range) Dose | 50 (40-92.6) | 50 (40-87.1) |
| | N (%) Location=Left | 45 (57.0) | 35 (50.7) |
| | Right | 34 (43.0) | 33 (47.8) |
| | Both | 0 (0.0) | 1 (1.5) |
| Medication Information (available in only n=83 patients) | | | |
| N | | 39 | 44 |
| Medication | N (%) Yes | 6 (15.4) | 11 (25.0) |
| Aspirin | N (%) Yes | 0 (0.0) | 1 (2.3) |
| ACE-Inhibitor | N (%) Yes | 3 (7.7) | 7 (15.9) |
| Beta Blocker | N (%) Yes | 3 (7.7) | 0 (0.0) |
| Angiotensin Blocker | N (%) Yes | 1 (2.6) | 4 (9.1) |
| CA Channel Antagonist | N (%) Yes | 3 (7.7) | 0 (0.0) |

| | | | |
|-----------------------------------|--------------------------|-----------|-----------|
| Diuretic | N (%) Yes | 2 (5.1) | 3 (6.8) |
| Alpha-Blocker | N (%) Yes | 0 (0.0) | 0 (0.0) |
| Hydralazine | N (%) Yes | 0 (0.0) | 0 (0.0) |
| Clonidine | N (%) Yes | 0 (0.0) | 0 (0.0) |
| Spironolactone | N (%) Yes | 0 (0.0) | 0 (0.0) |
| Statin | N (%) Yes | 1 (2.6) | 1 (2.3) |
| Other Medications | N (%) Yes | 0 (0.0) | 1 (2.3) |
| Outcomes | | | |
| Completed Study as Planned | N (%) Yes | 90 (90.0) | 88 (88.0) |
| | Reason=LVEF | 2 | 2 |
| | Stopped Trastuzumab | 2 | 6 |
| | Metastatic Disease | 5 | 1 |
| | Wants Cardiac Monitoring | 0 | 1 |
| | Declined Treatment | 0 | 1 |
| | Location Changed | 1 | 1 |

* Other risk factors include: arrhythmia, mitral and aortic stenosis, myxoma, polycystic ovarian syndrome, pulmonary embolism, supraventricular tachycardia, thrombophlebitis and triple bypass hypocholesterolemia

Table S2. Analysis of change in LVEF From Baseline (Per protocol population).

| Factor | | Estimate (std error) | 95% CI | p-value |
|---|------------------|-----------------------------|---------------|----------------|
| Intervention Arm Time from Baseline Interaction | Q3 vs Q4-monthly | −0.98 (0.66) | | 0.14 |
| | Per day | −0.017 (0.003) | | <0.001 |
| | Interaction | 0.0004 (0.004) | | 0.92 |
| Intervention Arm Time from Baseline | Q3 vs Q4-monthly | −0.94 (0.52) | −1.96 to 0.09 | 0.074 |
| | Per day | −0.01667 (0.0020) | | <0.001 |